Company Description
Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom.
It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the treatment of head and neck cancer.
The company also focuses on the development of T-cell therapies directed to PRAME (ADP-600) and CD70 (ADP-520).
It has strategic collaboration with Galapagos to clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel produced on Galapagos’ decentralized manufacturing platform (ADP-5701) in patients with head and neck cancer; collaboration and license agreement with Noile-Immune Biotech, Inc. and strategic alliance agreement with the MD Anderson Cancer Center.
Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
| Country | United Kingdom |
| Founded | 2008 |
| IPO Date | May 6, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 506 |
| CEO | Adrian G. Rawcliffe |
Contact Details
Address: 60 Jubilee Avenue, Milton Park Abingdon, OX14 4RX United Kingdom | |
| Phone | 44 12 3543 0000 |
| Website | adaptimmune.com |
Stock Details
| Ticker Symbol | ADAP |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001621227 |
| CUSIP Number | 00653A107 |
| ISIN Number | US00653A1079 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Adrian G. Rawcliffe | Chief Executive Officer and Director |
| William C. A. Bertrand Jr., Esq., J.D. | Chief Operating Officer and Chief Compliance Officer |
| Cintia Piccina Pharm.D. | Chief Commercial Officer |
| Dr. Helen Katrina Tayton-Martin MBA, Ph.D. | Co-Founder |
| Joanna Brewer Ph.D. | Chief Scientific Officer |
| Dr. Juli P. Miller Ph.D. | Vice President of Corporate Affairs and Investor Relations |
| Kerry Sharp | Senior Vice President and General Counsel |
| Dana Lynch | Senior Director of Corporate Communications |
| John Lunger | Chief Patient Supply Officer |
| Dr. Elliot Norry B.A., M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 29, 2025 | 8-K | Current Report |
| May 15, 2025 | SCHEDULE 13G/A | Filing |
| May 13, 2025 | 10-Q | Quarterly Report |
| May 13, 2025 | 8-K | Current Report |
| May 1, 2025 | 8-K | Current Report |
| Apr 25, 2025 | ARS | Filing |
| Apr 25, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 18, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Apr 15, 2025 | PRE 14A | Other preliminary proxy statements |
| Apr 14, 2025 | 8-K | Current Report |